Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 1/20 | 0.33 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261909 | 0.71 | MAPK1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL14812010 | 0.71 | MAPK1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL14812009 | 0.71 | MAPK1 (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL17004439 | 0.67 | MAPK1 (0.31) | LMNASMN1; SMN2 | |
| SCHEMBL5564424 | 0.66 | ALDH1A1 (0.67) | ALDH1A1LMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL15665598 | 0.66 | ALDH1A1 (0.34) | ALDH1A1LMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL9056774 | 0.65 | CHRNB2 (0.33) | POLB | |
| SCHEMBL16963847 | 0.62 | GRM5 (0.39) | ALDH1A1LMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL11847774 | 0.62 | ALDH1A1 (0.37) | ALDH1A1LMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL4438715 | 0.61 | ALDH1A1 (0.53) | ALDH1A1LMNAPOLBHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | ALDH1A1 337/4885LMNA 2244/4885POLB 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.